Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction
This trial is active, not recruiting.
|Condition||coronary artery disease|
|Sponsor||Medstar Research Institute|
|Start date||October 2009|
|End date||October 2011|
|Trial size||120 participants|
|Trial identifier||NCT01003717, REWARDS EMI|
Single-center registry of patients treated with at least one Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome at the Washington Hospital Center, with the aim of assessing clinical success and safety at 30 days, 6 months and annually for up to 3 years post Endeavor Stent implantation.
Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
Evaluation of Major Adverse Cardiac Events following implantation of at least one Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
time frame: Follow Up
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients, male or female, >18 years of age - Patients presenting with acute coronary syndrome (ACS), where ACS is defined as ST segment deviation of >1mm or an elevation of the isoenzymes greater than 2x upper limit of normal - Patients who received at least one Endeavor drug-eluting stent at the Washington Hospital Center Exclusion Criteria: - N/A
|Official title||REWARDS-EMI (Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction)|
|Principal investigator||Ron Waksman, MD|
|Description||Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES).Zotarolimus-eluting stents have shown promising results in randomized clinical trails, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with Sirolimus-eluting stents. While short-term and 1 year registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Endeavor® Stent as primary treatment for ACS for up to 3 years post initial stent implantation.|
Call for more information